Altre lingue Integrum AB

Azioni

INTEG B

SE0009807266

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:29:41 24/04/2024			Variaz. 5gg	Var. 1 gen.
61,4 ^SEK	-0,97%		+1,32%	+34,50%

26/03	Integrum (publ) stipula un accordo commerciale con AMI Technologies per introdurre il Sistema Implantare OPRATM in Israele	CI
29/02	Integrum AB (publ) riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 31 gennaio 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Integrum: Anchoring its position as niche leader	11/04
Integrum expands its product offering into the Israeli market	26/03
Integrum Enters a Commercial agreement with AMI Technologies to introduce the OPRATM Implant System in Israel	26/03
Health economic study shows positive outcome using Integrum's OPRA[TM] Implant System over socket prostheses in transfemoral amputees	19/03
Integrum Q3 - In line and no estimate changes	01/03
A new record revenue quarter with 61% growth	29/02
Integrum AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	29/02
Integrum AB, Invitation to the Third Quarter 2023, 24 Results Presentation	26/02
Integrum AB: Invitation to the Third Quarter 2023/24 Results Presentation	23/02
Integrum has sold and delivered OPRA[TM] Implant Systems to a value of SEK 3.5 million to Center of Excellence in Ukraine	31/01
Integrum Sells and Delivers Opratm Implant Systems to A Value of SEK 3.5 Million to Center of Excellence in Ukraine	31/01
Integrum establishes Center of Excellence in Ukraine	20/12
Integrum AB Establishes Center of Excellence in Ukraine	20/12
Integrum's MDR certification is completed for the OPRA[TM] Implant System	15/12
Integrum Q2 - Alive and kicking	05/12
Record sales and profitability	04/12
Integrum AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	04/12
Integrum AB changes Certified Adviser to Carnegie Investment Bank AB (publ)	30/11
Integrum AB: Invitation to the Second Quarter 2023/24 Results Presentation	28/11
Integrum plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data	13/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Integrum AB

Azioni

INTEG B

SE0009807266

Altre lingue

Filtri